madman
Super Moderator
Nandrolone decanoate administration does not attenuate muscle atrophy during a short period of disuse
Astrid M. H. Horstman, Evelien M. P. Backx, Joey S. J. Smeets, Gabriel N. MarzucaNassr, Janneau van Kranenburg, Douwe de Boer, John Dolmans, Tim Snijders, Lex B. Verdijk, Lisette C. P. G. M. de Groot, Luc J. C. van LoonID*
Objective
To assess whether a single intramuscular injection of nandrolone decanoate prior to immobilization can attenuate the loss of muscle mass and strength in vivo in humans.
Design, setting and participants
Thirty healthy (22±1 years) men were subjected to 7 days of one-legged knee immobilization by means of a full leg cast with (NAD, n = 15) or without (CON, n = 15) prior intramuscular nandrolone decanoate injection (200 mg).
Measures
Before and immediately after immobilization, quadriceps muscle cross-sectional area (CSA) (by means of single-slice computed tomography (CT) scans of the upper leg) and one-legged knee extension strength (one-repetition maximum [1-RM]) were assessed for both legs. Furthermore, muscle biopsies from the immobilized leg were taken before and after immobilization to assess type I and type II muscle fiber cross-sectional area.
Results
Quadriceps muscle CSA decreased during immobilization in both CON and NAD (-6±1% and -6±1%, respectively; main effect of time P<0.01), with no differences between the groups (time×treatment interaction, P = 0.59). Leg muscle strength declined following immobilization (-6±2% in CON and -7±3% in NAD; main effect of time, P<0.05), with no differences between groups (time×treatment interaction, P = 0.55).
Conclusions
This is the first study to report that nandrolone decanoate administration does not preserve skeletal muscle mass and strength during a short period of leg immobilization in vivo in humans.
Conclusions
Administration of a single bolus of nandrolone decanoate (200 mg) prior to a short period of disuse does not attenuate muscle mass or strength loss. This is the first study to report no preservation of skeletal muscle mass and strength following nandrolone decanoate administration during a short period of leg immobilization in vivo in humans.
They only used a single intramuscular injection of nandrolone decanoate (200 mg).
Astrid M. H. Horstman, Evelien M. P. Backx, Joey S. J. Smeets, Gabriel N. MarzucaNassr, Janneau van Kranenburg, Douwe de Boer, John Dolmans, Tim Snijders, Lex B. Verdijk, Lisette C. P. G. M. de Groot, Luc J. C. van LoonID*
Objective
To assess whether a single intramuscular injection of nandrolone decanoate prior to immobilization can attenuate the loss of muscle mass and strength in vivo in humans.
Design, setting and participants
Thirty healthy (22±1 years) men were subjected to 7 days of one-legged knee immobilization by means of a full leg cast with (NAD, n = 15) or without (CON, n = 15) prior intramuscular nandrolone decanoate injection (200 mg).
Measures
Before and immediately after immobilization, quadriceps muscle cross-sectional area (CSA) (by means of single-slice computed tomography (CT) scans of the upper leg) and one-legged knee extension strength (one-repetition maximum [1-RM]) were assessed for both legs. Furthermore, muscle biopsies from the immobilized leg were taken before and after immobilization to assess type I and type II muscle fiber cross-sectional area.
Results
Quadriceps muscle CSA decreased during immobilization in both CON and NAD (-6±1% and -6±1%, respectively; main effect of time P<0.01), with no differences between the groups (time×treatment interaction, P = 0.59). Leg muscle strength declined following immobilization (-6±2% in CON and -7±3% in NAD; main effect of time, P<0.05), with no differences between groups (time×treatment interaction, P = 0.55).
Conclusions
This is the first study to report that nandrolone decanoate administration does not preserve skeletal muscle mass and strength during a short period of leg immobilization in vivo in humans.
Conclusions
Administration of a single bolus of nandrolone decanoate (200 mg) prior to a short period of disuse does not attenuate muscle mass or strength loss. This is the first study to report no preservation of skeletal muscle mass and strength following nandrolone decanoate administration during a short period of leg immobilization in vivo in humans.
They only used a single intramuscular injection of nandrolone decanoate (200 mg).
